Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: A meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 10, 2013, Pages 1257-1266

  Hwang, Thomas J ^a   Wares, D F ^b   Jafarov, A ^b   Jakubowiak, W ^b   Nunn, P ^c   Keshavjee, S ^d  

^a HARVARD UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Global Consulting Cerner   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adverse drug reactions; Cycloserine; Drug resistance; Terizidone; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; OXYTETRACYCLINE; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

ANEMIA; ANXIETY; ARGENTINA; ASIAN; CENTRAL NERVOUS SYSTEM DISEASE; CHINA; CONVULSION; DEPRESSION; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAST ASIAN; HONG KONG; HUMAN; INDIA; IRAN; MENTAL DISEASE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NEUROPATHY; PERU; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RUSSIAN FEDERATION; SEIZURE; SIDE EFFECT; SINGAPORE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TAIWAN; TREATMENT PLANNING; TUBERCULOSIS; TURKEY (REPUBLIC); UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; UZBEKISTAN;

ANTIBIOTICS, ANTITUBERCULAR; CENTRAL NERVOUS SYSTEM DISEASES; CYCLOSERINE; HUMANS; ISOXAZOLES; MENTAL DISORDERS; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84884639643     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0863     Document Type: Review

References (55)

1. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. Mitnick C D, Castro K G, Harrington M, Sacks L V, Burman W. Randomized trials to optimize treatment of multidrugresistant tuberculosis. PLoS Med 2007; 4: 1730-1734.
3. Albouy R, Eloy P, Pestel M, Ravina A, Rey M. First clinical results obtained with cycloserine in the treatment of human tuberculosis. Antibiot Annu 1955-1956; 3: 148-152.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB 2008.402. Geneva, Switzerland: WHO, 2008.
5. Partners In Health/World Health Organization. Management of MDR-TB: A field guide. A companion document to guidelines for programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402a. Geneva, Switzerland: WHO, 2009.
6. Yee D, Vallquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side-effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
7. Murray F J. A pilot study of cycloserine toxicity: A United States Public Health Service cooperative clinical investigation. Am Rev Tuberc 1956; 74: 196-209.
8. Kendig I V, Charen S, Lepine L T. Psychological side effects induced by cycloserine in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1956; 73: 438- 441.
9. Yew W W, Wong C F, Wong P C, Lee J, Chau C H. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofl oxacin. Clin Infect Dis 1993; 17: 288-289.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
11. World Health Organization. Package leafl et: information for the user (cycloserine capsules 250 mg). WHOPAR Part 3 2007. Geneva, Switzerland: WHO, 2007.
12. Stroup D F, Berlin J A, Morton S C, et al., for the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA 2000; 283: 2008-2012.
13. Freeman M F, Tukey J W. Transformations related to the angular and the square root. Ann Math Statist 1950; 21: 607-611.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177-188.
15. Epstein I G, Nair K G, Boyd L J. The treatment of human pulmonary tuberculosis with cycloserine: progress report. Dis Chest 1956; 29: 241-257.
16. Lewis W C, Calden G, Thurston J R, Gilson W E. Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis. Dis Chest 1957; 32: 172-182.
17. Walker W C, Murdoch J M. Cycloserine in the treatment of pulmonary tuberculosis; a report on toxicity. Tubercle 1957; 38: 297-302.
18. Epstein I G, Nair K G, Boyd L J, Auspitz P. Cycloserine- isoniazid combination therapy in virgin cases of pulmonary tuberculosis. Dis Chest 1958; 33: 371-381.
19. Grove-White R J, Supramaniam J M. Cycloserine treatment of pulmonary tuberculosis in Asian patients. Tubercle 1958; 39: 213-215.
20. Ritchie J A, Campbell A E, Cuthbert J, Bruce L G. Treatment of drug-resistant cases of pulmonary tuberculosis with cycloserine and pyrazinamide. Tubercle 1958; 39: 289-295.
21. Weinberger M, Lindars D C, Pasha M A. Cycloserine in the treatment of drug-resistant cases of pulmonary tuberculosis. Tubercle 1958; 39: 96-102.
22. Holmes C X, Martin G E, Fetterhoff K I. The role of the cycloserine (seromycin) blood level in the treatment of pulmonary tuberculosis and the prevention and control of cycloserine ( seromycin) toxicity. Dis Chest 1959; 36: 591-593.
23. Craig J W, Williams H, Alston J M. Cycloserine treatment of out-patients with chronic drug resistant pulmonary tuberculosis. Tubercle 1961; 42: 7-13.
24. Somner A R, Brace A A. Ethionamide, pyrazinamide and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis. Tubercle 1962; 43: 345-360.
25. Ruiz R C. D-cycloserine in the treatment of pulmonary tuberculosis resistant to the standard drugs: A study of 116 cases. Dis Chest 1964; 45: 181-186.
26. Pines A. Treatment of pulmonary tuberculosis with cultures resistant to two or more drugs: A series of 44 patients. Tubercle 1965; 46: 131-142.
27. Ramakrishnan C V, Devadatta S, Evans C, et al. Cycloserine plus ethionamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli following previous chemotherapy. Tubercle 1967; 48: 114-127.
28. Horsfall P A. Treatment of resistant pulmonary tuberculosis in Hong Kong with regimens of second-line drugs. Tubercle 1972; 53: 166-173.
29. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
30. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
31. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofl oxacin/levofl oxacin-containing regimens. Chest 2000; 117: 744-751.
32. Tahaǒglu K, Törün T, Sevim T, et al. The treatment of multidrug- resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
33. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
34. Palmero D J, Ambroggi M, Brea A, et al. Treatment and followup of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-784.
35. Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8: 749-759.
36. Törün T, Güngör G, Özmen Ï, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
37. Chiang C-Y, Enarson D A, Yu M C, et al. Outcome of pulmonary multidrug-resistant tuberculosis: A 6-yr follow-up study. Eur Respir J 2006; 28: 980-985.
38. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS ONE 2007; 2: e1126.
39. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
40. Masjedi M R, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002- 2006. Int J Tuberc Lung Dis 2008; 12: 750-755.
41. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug- resistant tuberculosis treatment with a standardized regimen: A report from Iran. Am J Ther 2011; 18: e29-34.
42. Micheletti V, Teti V, Fenzi P, Usberti G. The therapy of pulmonary tuberculosis in psychopathic patients, using terizidone. Minerva Med 1968; 59: 2459-2465.
43. Hammerli A, Gallindo I S. [Treatment of resistant chronic tuberculosis. A new antitubercular agent: terizidone]. Rev Bras Med 1969; 26: 684-688. [Portuguese].
44. Rizzo A, Gomes A, Antunes G. [Cycloserine and terizidone in the treatment of pulmonary tuberculosis: clinical study of tolerance]. Rev Bras Med 1969; 26: 119-122. [Portuguese].
45. Briones F H. [Evaluation of secondary manifestations in patients treated with terizidone]. Rev Bras Med 1970; 27: 271- 275. [Portuguese].
46. Fossati C. [Terizidone in the therapy of chronic pulmonary tuberculosis]. G Ital Mal Torace 1971; 25: 195-204. [Italian].
47. Dumon J F, Aimone J, Dumon G. Preliminary note on Terizidone. Mars Med 1972; 109: 730-732.
48. Zrilić V, Mijatovíc M, Mirković S, Muzikravíc T. [Results of clinical trials of a new antitubercular agent, terizidone (Terivalidine)]. Plucne Bolesti Tuberk 1972; 24: 89-98. [Croatian].
49. Böszörményi M. Triple placebo test for comparison of side effects of terizidone (terivalidin) and cycloserine. Int J Clin Pharmacol 1973; 8: 37- 41.
50. Shmelev N A, Shabalova L N, Kolosovskaia V P. [Comparative clinical electroencephalographic study of cycloserine and terizidone tolerance]. Antibiotiki 1975; 20: 174-180. [Russian].
51. Galietti F, Giorgis G E, Oliaro A, et al. Tolerability to terizidone (TZ) in the treatment of pulmonary tuberculosis in dialyzed patients. Minerva Med 1991; 82: 477- 481.
52. World Health Organization. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. Geneva, Switzerland: WHO, 2012.
53. Hofmann S G, Meuret A E, Smits J A, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298-304.
54. Kushner M G, Kim S W, Donahue C, et al. D-cycloserine augmented therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62: 835-838.
55. Ressler K J, Rothbaum B O, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-1144.